AbbVie (NYSE:ABBV) Trading Up 2.1% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV)’s share price shot up 2.1% during mid-day trading on Tuesday . The stock traded as high as $215.80 and last traded at $213.7730. 7,152,122 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 7,036,760 shares. The stock had previously closed at $209.41.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s neuroscience business was highlighted as a key driver of first-quarter sales growth, with the segment up 26% year over year thanks to strong demand for Vraylar, migraine treatments, and Botox. Article: Here’s How Neuroscience Drugs Boost AbbVie’s Q1 Sales Growth
• Positive Sentiment: Several articles framed ABBV as a potentially undervalued dividend stock, suggesting investors may be looking past its higher earnings multiple because of its pipeline, cash flow, and income appeal. Article: 3 Stocks That May Be Priced Below Their Estimated Value In May 2026
• Neutral Sentiment: AbbVie was also identified as a trending stock in Zacks coverage, which mainly reflects elevated investor interest rather than a new fundamental catalyst. Article: Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
• Negative Sentiment: Evercore ISI slightly lowered its price target on AbbVie to $235 from $236, a modest negative signal that may temper some of the recent enthusiasm. Article: AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI

Analysts Set New Price Targets

A number of analysts recently weighed in on ABBV shares. Guggenheim reiterated a “buy” rating and set a $249.00 price target on shares of AbbVie in a research note on Friday, May 1st. Morgan Stanley increased their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Canaccord Genuity Group increased their price target on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Trading Up 2.1%

The stock has a market cap of $377.69 billion, a price-to-earnings ratio of 105.31, a PEG ratio of 0.73 and a beta of 0.32. The stock’s 50 day moving average is $209.82 and its two-hundred day moving average is $219.92.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio is presently 340.89%.

Insiders Place Their Bets

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

A number of large investors have recently made changes to their positions in ABBV. Norges Bank purchased a new position in shares of AbbVie in the 4th quarter valued at about $5,865,055,000. Wellington Management Group LLP increased its holdings in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Capital World Investors increased its holdings in shares of AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. increased its holdings in shares of AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.